IN8bio, Inc. logo

IN8bio, Inc.


Overview | Financials
Company Name IN8bio, Inc.
Symbol INAB
Currency USD
Price 1.04
Market Cap 45,884,444
Dividend Yield 0%
52-week-range 0.65 - 3.21
Industry Biotechnology
Sector Healthcare
CEO Mr. Tai-Wei Ho

An error occurred while fetching data.

About IN8bio, Inc.

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma

Related Stocks

Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc.


1.48 USD

Neoleukin Therapeutics, Inc. logo

Neoleukin Therapeutics, Inc.


3.49 USD

Cocrystal Pharma, Inc. logo

Cocrystal Pharma, Inc.


2.07 USD

Ocuphire Pharma, Inc. logo

Ocuphire Pharma, Inc.


1.71 USD


Numbers are in millions USD

Numbers are in millions USD